Minimizing Particulate Risk

Patients, clinicians, and regulators are all increasingly focused on the presence of particles in drug products, reflecting the critical importance of maintaining the highest standards of injectable medicine quality. While visible particles often draw immediate attention, visual inspection alone is not sufficient, as sub-visible particulate matter can present equally significant risks to patient safety, potentially leading to inflammatory responses, immunogenic reactions, and compromised therapeutic performance.

To effectively protect patients and ensure product integrity, it is essential to take a proactive approach to particulate risk management. This includes carefully evaluating raw materials, components, and container closure systems to identify and mitigate potential sources of contamination early in the development and manufacturing process.

Minimizing particulate risk is not only a regulatory expectation but a fundamental requirement for delivering safe, effective injectable therapies with confidence.